EP0331635A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Preparations for treating bladder cancer
Assignee: The University of Texas System
•
Filing: 1989-02-21
•
Granted: —
•
Expires: 2009-02-21
Abstract
Abstract The invention concerns a method for the treatment of bladder cancer by applying alpha-interferon (IFN- alpha ) hybrids, or especially liposomes containing such hybrids.
Inventors
- 👤 Isaiah Prof. Dr. Fidler
- 👤 John Dr. Johnson
- 👤 Rajiv Dr. Nayar
- 👤 Jerald Jay Prof. Dr. Killion
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 22:09
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0034; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/21; A61K38/212; A61K9/10; A61K9/127; A61P; A61P35/00
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
21 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament for the treatment of bladder cancer.
Claim 2
Dependent Claim
21 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament for the treatment of bladder cancer.
Claim 3
Dependent Claim
26 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament for the treatment of superficial bladder cancer according to claim 1.
Claim 4
Dependent Claim
29 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament for the treatment of an invasive or metastatic bladder cancer according to claim 1.
Claim 5
Dependent Claim
25 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament which is applicable by intrabladder administration, according to claim 1.
Claim 6
Dependent Claim
9 words
The use of IFN-α B₁B₂D₃D₄ according to claim 1.
Claim 7
Dependent Claim
9 words
The use of IFN-α B₁B₂D₃B₄ according to claim 1.
Claim 8
Dependent Claim
33 words
The use of an IFN-α BBDD or BBDB hybrid for the manufacture of a medicament allowing for administration of the IFN-α hybrid in dosages of 10⁷ to 10⁸ units according to claim 1.
Claim 9
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective amount of an IFN-α BBDD or BBDB hybrid, suitable for the treatment of bladder cancer, which is in the form of a liposome composition.
Claim 10
Dependent Claim
31 words
A pharmaceutical composition comprising a therapeutically effective amount of an IFN-α BBDD or BBDB hybrid, suitable for the treatment of bladder cancer, which is in the form of a liposome composition.
Claim 11
Dependent Claim
108 words
A pharmaceutical liposome composition according to claim 8, consisting of a) a IFN-α BBDD or IFN-α BBDB hybrid and b) a phospholipid of the formula wherein n is one, two or three, R₁ and R₂ independently of each other represent alkyl, alkenyl or acyl each having 10-20 carbon atoms, and Y ⊕ is the cation of a pharmaceutically acceptable base, c) a phospholipid of the formula wherein n is two, three or four, R₁ and R₂ are defined as above and R₃, R₄ and R₅ represent hydrogen or C₁-C₄-alkyl, and, optionally, a pharmaceutically acceptable carrier solution buffered to pH 7.0-7.8 and, optionally, pharmaceutically acceptable carriers in solid form.
Claim 12
Dependent Claim
33 words
Process for the preparation of a pharmaceutical composition according to any one of claims 8 to 9, characterized in that an IFN-α BBDD or BBDB hybrid are pharmaceutically processed according to conventional methods.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.